Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Strides Pharma re-enters injectable biz by infusing Rs 280 crore for controlling stake in Stelis Biopharma

      Strides Pharma re-enters injectable biz by infusing Rs 280 crore for controlling stake in Stelis Biopharma

      Farhat Nasim21 Sept 2019 12:04 PM IST
      Bengaluru-based Strides has already invested USD 35 million (about Rs 245 crore) for a 43 per cent ownership in Stelis.New Delhi: Strides Pharma...
      Biocon Chief Kiran Shaw, FM Nirmala Sitharaman in tiff over E-Cigarette ban

      Biocon Chief Kiran Shaw, FM Nirmala Sitharaman in tiff over E-Cigarette ban

      Farhat Nasim20 Sept 2019 5:01 PM IST
      New Delhi: Biocon Chief Kiran Mazumdar Shaw recently got into a spat with the Finance Minister Nirmala Sitharaman on Thursday. The minister defended...
      Novartis combination therapy with Vildagliptin-Metformin shows positive results for Type 2 Diabetes

      Novartis combination therapy with Vildagliptin-Metformin shows positive results for Type 2 Diabetes

      Farhat Nasim20 Sept 2019 9:45 AM IST
      The vildagliptin and metformin dual therapy are used when the patient’s T2DM is insufficiently controlled by metformin monotherapy.Mumbai: Novartis...
      Police protection for Drug Regulators, Inspectors, recommends CDSCO committee

      Police protection for Drug Regulators, Inspectors, recommends CDSCO committee

      Farhat Nasim19 Sept 2019 3:17 PM IST
      New Delhi: Taking cognizance of the grave concern of providing security and protection to Drug inspectors from threats, the Drugs Consultative...
      GSK receives USFDA panel backing for OTC nicotine oral spray for smoking de-addiction

      GSK receives USFDA panel backing for OTC nicotine oral spray for smoking de-addiction

      Farhat Nasim19 Sept 2019 9:30 AM IST
      Johnson & Johnson (JnJ), GSK Plc's developmental partner, sell the over-the-counter nicotine oral spray in 45 countries, excluding the United...
      Apollo to separate out its pharmacy business, seeks shareholders nod

      Apollo to separate out its pharmacy business, seeks shareholders nod

      Farhat Nasim18 Sept 2019 5:37 PM IST
      New Delhi: Based on the directions of National Company Law Tribunal (NCLT), Apollo Hospitals Enterprise Ltd (AHEL) has proposed to hive off its...
      Manufacture of Class C, D medical devices: CDSCO makes Centre the licensing authority

      Manufacture of Class C, D medical devices: CDSCO makes Centre the licensing authority

      Farhat Nasim17 Sept 2019 5:03 PM IST
      New Delhi: Through a recent Gazette notification, the Central Drugs Standard Control Organisation (CDSCO) has apprised that medical device...
      AstraZeneca Farxiga gets USFDA fast track designation for heart failure

      AstraZeneca Farxiga gets USFDA fast track designation for heart failure

      Farhat Nasim16 Sept 2019 9:32 AM IST
      The grant comes after AstraZeneca made strides last month towards its goal of adding heart failure to the conditions that can be treated by Farxiga,...
      Diabetes Management: Sanofi, Abbott team up to integrate glucose sensing, insulin delivery technologies

      Diabetes Management: Sanofi, Abbott team up to integrate glucose sensing, insulin delivery technologies

      Farhat Nasim16 Sept 2019 9:30 AM IST
      Sanofi and Abbott will take an approach to connected care by developing tools that combine the revolutionary FreeStyle Libre technology with insulin...
      Lundbeck to acquire migraine drugmaker Alder BioPharma for USD 1.95 billion

      Lundbeck to acquire migraine drugmaker Alder BioPharma for USD 1.95 billion

      Farhat Nasim16 Sept 2019 9:20 AM IST
      New Delhi: Lundbeck and Alder BioPharmaceuticals recently announced a definitive agreement for Lundbeck to acquire Alder. The transaction is valued...
      CDSCO apprises about the Continuity in validity of Written Confirmation Certificate for API consignments for Exports

      CDSCO apprises about the Continuity in validity of Written Confirmation Certificate for API consignments for Exports

      Farhat Nasim15 Sept 2019 10:36 AM IST
      New Delhi: Through a recent circular, the Central Drugs Standard Control Organisation (CDSCO) has apprised about maintaining the continuity in the...
      One Drug, Multiple Manufacturing Facilities: CDSCO approves manufacturing of new drug in additional sites

      One Drug, Multiple Manufacturing Facilities: CDSCO approves manufacturing of new drug in additional sites

      Farhat Nasim14 Sept 2019 4:38 PM IST
      New Delhi: The apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has apprised drug makers that they can manufacture a new...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok